Slater Technology Fund-backed company to be acquired by Novartis

A SLATER TECHNOLOGY FUND-backed company, Cadent Therapeutics, has entered into an agreemnt to be acquired by Novartis in a deal worth up to $770 million.
A SLATER TECHNOLOGY FUND-backed company, Cadent Therapeutics, has entered into an agreemnt to be acquired by Novartis in a deal worth up to $770 million.
PROVIDENCE – The Cambridge, Mass.-based company Cadent Therapeutics has entered into an agreement to be acquired by Novartis in a deal worth up to $770 million, Slater Technology Fund announced Friday. The company was formed through a merger with the Slater Technology Fund-backed company Mnemosyne Pharmaceuticals. Mnemosyne developed a drug-discovery program targeting the creation of…

Want More?

Subscribe or register with Providence Business News to keep reading.

REGISTER
for 2 more stories

Subscribe now for $1 for 4 weeks
Already a Subscriber? Login now

Purchase NowWant to share this story? Click Here to purchase a link that allows anyone to read it on any device whether or not they are a subscriber.

- Advertisement -

No posts to display